MEDIA_REFRESH_DATA_PRESS_RELEASE
Media
U.S. News Room
Press Releases
Fri May 29 00:00:00 GMT-05:00 2020
ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase 2 DESTINY-Gastric01 Trial
Download
Fri May 29 00:00:00 GMT-05:00 2020
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial
Download
Fri May 29 00:00:00 GMT-05:00 2020
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial
Download
Fri May 29 00:00:00 GMT-05:00 2020
ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial
Download
Fri May 29 00:00:00 GMT-05:00 2020
Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Non-Small Cell Lung Cancer
Download
Thu May 28 00:00:00 GMT-05:00 2020
Daiichi Sankyo and Syneos Health® Form Strategic Coalition for Development of Daiichi Sankyo’s ADC Oncology Pipeline
Download
Mon May 25 00:00:00 GMT-05:00 2020
Daiichi Sankyo Launches ENHERTU® in Japan for Patients with HER2 Positive Unresectable or Metastatic Breast Cancer
Download
Fri May 22 00:00:00 GMT-05:00 2020
Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Cannon Research Institute
Download
Thu May 21 00:00:00 GMT-05:00 2020
ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer
Download
Mon May 18 00:00:00 GMT-05:00 2020
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Download